



# AJOONI BIOTECH LIMITED

Regd. Office: D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.)

Phone: 0172-5020758-69 Website: [www.ajoonibiotech.com](http://www.ajoonibiotech.com)

E-mail: [ajooni.biotech@gmail.com](mailto:ajooni.biotech@gmail.com) / [info@ajoonibiotech.com](mailto:info@ajoonibiotech.com)

CIN: L85190PB2010PLC040162

February 07, 2024

To,  
National Stock Exchange of India Ltd  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400051

Dear Sir / Madam,

**SYMBOL: AJOONI**

**Sub.: Approval of Un-audited Financial Results for the quarter ended December 31, 2023.**

Dear Sir,

Pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015, we wish to inform that the Board of Directors of the Company at their meeting held on Wednesday, February 07, 2024 at the Registered Office of the company have considered and approved the Un-audited Financial Results quarter ended December 31, 2023. In this regards, we are enclosing herewith:

1. Un-audited Financial Results for the quarter ended December 31, 2023 as recommended by the Audit Committee.
2. Limited Review Report for the quarter ended December 31, 2023.

You are requested to kindly take the same on record.

Thanking You,  
Yours Truly,  
For Ajooni Biotech Limited

Jasjot Singh  
Managing Director  
DIN: 01937631

**AJOONI BIOTECH LIMITED**

**CIN : L85190PB2010PLC040162**

**STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER 2023 (In Lakhs)**

	PARTICULARS	Quarter Ended					Year Ended (Audited)
		31.12.2023	30.09.2023	31.12.2022	Period Ended (UnAudited)	Period Ended (Unaudited)	31.03.2023
					31.12.2023	31.12.2022	
<b>I</b>	<b>Income</b>						
	Revenue from operations	2,005.04	1,947.99	1,062.97	6,053.30	3,323.18	7448.77
	Other income	157.43	29.00	2.13	193.65	3.25	29.41
	<b>Total income from operations</b>	<b>2,162.47</b>	<b>1,976.99</b>	<b>1,065.10</b>	<b>6,246.95</b>	<b>3,326.43</b>	<b>7,478.18</b>
<b>II</b>	<b>Expenses</b>						
	Cost of Material Consumed	1,813.35	1,743.89	915.72	5,459.95	2,754.82	6,612.12
	Change In Inventories	29.82	15.90	(42.09)	26.64	(28.33)	(37.85)
	Employee benefit expenses	61.40	51.08	51.48	166.11	149.79	176.11
	Finance costs	12.08	19.19	12.52	44.65	35.82	47.83
	Depreciation and amortization expenses	21.34	21.34	26.45	63.59	76.71	100.49
	Payment to NSE	-	-	-	-	-	-
	Other expenses	166.21	73.51	90.35	336.23	264.60	421.81
	<b>Total expenses</b>	<b>2,104.20</b>	<b>1,924.91</b>	<b>1,054.43</b>	<b>6,097.17</b>	<b>3,253.41</b>	<b>7,320.51</b>
III	<b>Profit/(Loss) before exceptional items and tax</b>	<b>58.27</b>	<b>52.08</b>	<b>10.67</b>	<b>149.78</b>	<b>73.02</b>	<b>157.67</b>
IV	<b>Exceptional items</b>						
V	<b>Profit/(Loss) before tax</b>	<b>58.27</b>	<b>52.08</b>	<b>10.67</b>	<b>149.78</b>	<b>73.02</b>	<b>157.67</b>
VI	<b>Tax expenses</b>						
	a) Current tax	15.14	12.50	2.77	27.64	18.9852	54.24
	b) Deferred tax	0.85	0.89	2.91	2.50	4.51	9.02
	b) Mat Credit				-	-	
VII	<b>Net Profit/(Loss) for the period/year</b>	<b>43.98</b>	<b>40.47</b>	<b>10.81</b>	<b>124.64</b>	<b>58.54</b>	<b>112.45</b>
VIII	<b>Other comprehensive income (net of tax)</b>						
	Items that will not be reclassified to profit or loss:				(162.77)	-	186.07
	<b>Total other comprehensive income</b>				(162.77)	-	
IX	<b>Total comprehensive income for the period/year (VII+VIII)</b>	<b>43.98</b>	<b>40.47</b>	<b>10.81</b>	<b>(38.13)</b>	<b>58.54</b>	<b>298.52</b>
X	<b>Paid-up equity share capital (face value of the share shall be indicated)</b>	<b>1,752.27</b>	<b>1,752.27</b>	<b>1,752.27</b>	<b>1,752.27</b>	<b>1,752.27</b>	<b>1,752.27</b>
XI	<b>Other equity (excluding revaluation reserve)</b>	<b>2,361.76</b>	<b>2,332.55</b>	<b>2,180.36</b>	<b>2,361.76</b>	<b>2,180.36</b>	<b>2,414.66</b>
XII	<b>EPS in Rs. (Face Value of Rs.10/- each)*</b>						
	-Basic	0.25	0.23	0.06	0.71	0.33	1.94



7764 TM

-Diluted	0.25	0.23	0.06	0.71	0.33	1.94
<b>Notes:</b>						
1. The above results are as per Regulation 33 of the SEBI (LODR) Regulations, 2015 as amended and have been taken on record by Board of Directors at its meeting held on 07.02.2024 after being reviewed by the Audit Committee.						
2. The company is having single segment in accordance with IND AS 108 "operating segments". and therefore segment reporting is not applicable to the Company.						
3. Due to re-grouping of schedules, and as per applicability of IND-AS, there has been a difference in the figures as reported earlier.						

Date: 07.02.2024

Place : Mohali

For Ajooni Biotech Limited

Jasjot Singh  
 Managing Director  
 DIN:  
 01937631



## Statement of Assets and Liabilities

For the Year ended on 31st December 2023

PARTICULARS		in Rs. lakhs	
		31ST DECEMBER 2023	31ST MARCH 2023
<b>I. ASSETS</b>			
<b>(1)</b>	<b><u>Non - Current Assets</u></b>		
-	a) Property, Plant and Equipment	588.96	628.91
-	b) Capital Work In Progress	77.50	26.19
-	c) Investment Property		-
-	d) Goodwill		-
-	e) Other Intangible Assets		-
-	f) Intangible Assets Under Development		-
-	g) Biological Assets other than Bearer Plants		-
-	h) Financial Assets		
	(1) Investments	109.38	373.72
	(2) Trade Receivables		-
	(3) Loans		-
	(4) Other Financial Assets	640.00	1,200.00
	i) Deferred Tax Asset (net)	29.70	27.20
	j) Other Non Current Asset	230.00	150.00
<b>(2)</b>	<b><u>Current Assets</u></b>		
	a) Inventories	1,139.51	699.40
	b) Financial Assets		
	(1) Investments		
	(2) Trade Receivables	2,371.62	2,055.11
	(3) Cash & Cash Equivalent	135.85	30.93
	(4) Bank Balances other than (iii) above		
	(5) Loans	366.27	403.35
	(6) Other Financial Asset		18.41
	c) Current Tax Assets (net)		-
	d) Other Current Asset	178.25	259.93



	TOTAL	5,867.04	5,873.14
<b><u>II EQUITY AND LIABILITIES</u></b>			
<b>(1)</b>	<b><u>Equity</u></b>		
	a) Equity Share Capital	1,752.27	1,752.27
	b) Other Equity	2,361.76	2,414.66
<b>(2)</b>	<b><u>Non-Current Liabilities</u></b>		
	a) Financial Liabilities		
	(1) Borrowings	204.08	174.66
	(2) Trade Payables		
	(3) Other Financial Liabilities		
	b) Employee Benefit Obligations	10.61	10.61
	c) Deferred Tax Liability (net)		-
	d) Other Non Current Liability		-
<b>(3)</b>	<b><u>Current Liabilities</u></b>		
	a) Financial Liabilities		
	(1) Borrowings	105.17	343.04
	(2) Trade Payables	1,376.61	1,011.11
	(3) Other Financial Liabilities		
	b) Employee Benefit Obligations	2.40	2.40
	c) Other Current Liabilities	26.50	110.16
	d) Current tax liabilities (Net)	27.64	54.24
	<b>TOTAL</b>	<b>5,867.04</b>	<b>5,873.14</b>

Date: 07.02.2024

Place: Mohali

For Ajooni Biotech Limited



Jasjot Singh

Managing Director

DIN: 01937631



# Harjeet Parvesh & Company

CHARTERED ACCOUNTANTS

(A PEER REVIEWED FIRM)

## Limited Review Report on Standalone Financial Results

### To Board of Directors of M/s Ajooni Biotech Limited

We have reviewed the Standalone Un-Audited Financial Result of M/s. **Ajooni Biotech Limited** having its Regd. Office at D-118, Industrial Area, Phase VII, Mohali, Punjab-160055 for the Quarter ended 31<sup>ST</sup> December 2023 ("the Statement") attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015(as amended), including relevant circulars issued by the Securities and Exchange Board of India ('SEBI') from time to time.

This statement is the responsibility of company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Engagement to "Review of Interim Financial Information performed by the independent auditor of the entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material mis-statement. A review is limited primarily to inquiries of company personal and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Standalone-audited Financial Result prepared in accordance with applicable Accounting Standards i.e Indian Accounting Standards (' Ind AS') prescribed under section 133 of Companies Act, 2013, read with relevant rules issued there under and others recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Harjeet Parvesh & Co.  
Chartered Accountants



CA Harjeet Parvesh  
Partner

M.No 547759

Date : 07.02.2024

UDIN : 24547759BKFM MY6730

House No. 1122, Sector 71, Mohali

Mobile : 096460-27023, 098120-27023 | E-mail : harjeetca@yahoo.com